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as commonly applied, Markov models are used to deter-
mine if the new intervention is cost-effective if used in-
stead an old one at one point in the patient’s lifetime.
These models do not attempt to determine the lifetime
optimal treatment pathway for treating the disease. We
show how Markov decision models can be used to de-
velop an optimal treatment pathway, by assigning a
treatment option to each health state so as to maximize
overall net benefit. We will demonstrate how to derive
the optimal treatment pathway using dynamic program-
ming. We will present an illustrative example of the use
Markov decision model for a chronic disease such as
HIV. We will discuss some potential ethical issues that
could be raised by the optimal policies derived from
Markov decision models. We will conclude the workshop
with an interactive discussion of the benefits and draw-
backs of Markov decision models.
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OBJECTIVES: Participants will learn how to collect, an-
alyze, and use compliance data to perform per protocol
analyses that can demonstrate effectiveness and shape
models based on treatment persistence. Examples will in-
clude effectiveness for alcoholism, AIDS, cardiovascular
and mental illnesses.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who evaluate treatment outcomes, pharmacoeco-
nomic specialists who evaluate treatment costs, and other
health outcomes professionals.
Many people are negligent “partial compliers” who miss
doses regularly or intermittently despite the best inten-
tions and an understanding of the importance of taking
medication. In addition, long-term persistence with chronic
treatments is poor. These two manifestations of poor
compliance, confound assessment of drug effects, result
in poor quality medical care, and affect the overall cost of
care. Poorly compliant patients, because of their non-
response to drug treatment, advance to the uppermost
steps of stepped-care schemes, incurring needless diag-
nostic costs and treatment costs. The clinical and eco-
nomic consequences of poor compliance can range from
trivial to catastrophic, depending upon drug, disease and
its severity, and co-morbidities. Actual dose-taking and
dose-timing data collected from individuals can be linked
to efficacy parameters to stratify treatment effectiveness
based on compliance. The importance of using real-time
compliance data in outcomes analyses will be described
with examples from electronic compliance techniques.
Examples will include use of compliance data to demon-
strate value to patients and providers, as well as the phar-
maceutical industry.
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OBJECTIVES: Incorporating additional information
from the outcomes research literature (i.e. pharmacoeco-
nomics, pharmacoepidemiology, and quality of life) into
drug information resources used by clinical practitioners
presents a unique challenge. The objective of this work-
shop is to describe the complex issues involved when pro-
viding outcomes research information to clinicians who
are involved in drug therapy selection. Based on the expe-
riences of the presenters, cautionary statements about
meta analysis in outcomes research, with application to
heart failure, will be provided.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers interested in the epidemiologic, economic, and quality
of life aspects of heart failure, as well as those interested
in meta analysis and comparability of studies for clinical
practice and decision-making.
The practical applicability of outcomes research for clini-
cians represents a significant challenge. Drug information
sources could assist in making outcomes research find-
ings both succinct and “user friendly” if there were suffi-
cient literature and a means for compiling the salient
findings. The medical and pharmacy literature has an
abundant amount of information on heart failure and re-
lated treatments. Thus, it would appear that outcomes re-
search in heart failure could serve as a test case for pro-
ducing practical guidance for clinicians; however, a
number of general issues need to be addressed. How
should one objectively determine inclusion/exclusion cri-
teria for research studies? When should meta analysis be
performed and on what outcomes? When should findings
be reported for drug classes rather than individual
agents? There are also a number of questions that are
specific to heart failure. How and to what extent should
the severity of patients be used to group or stratify find-
ings? How should data on comorbidites be incorporated?
These questions will be explored in general and as part of
a heart failure case study.
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OBJECTIVES: In this workshop, we will (1) lay out the
set of conditions for assessing the quality of models, (2)
provide examples from the Duke Stroke Policy Model of
how these conditions may be met, and (3) engage partici-
pants in a discussion of cases in other clinical areas.
PARTICIPANTS WHO WOULD BENEFIT: Those who
develop and use decision/cost-effectiveness models.
In an ideal world all clinical decisions would be based on
evidence from large comprehensive scientific studies. In
the complex world of actual practice—the world of phar-
macoeconomics—such evidence is often impractical or
impossible to obtain. Models are used to help decision-
makers make plausible and useful inferences in the ab-
sence of perfect information. Despite the broad applica-
tion of models in this context, the process and conclusions
of modeling exercises are frequently suspect. Concerns
include: (1) failure to use the best available data; (2) inac-
cessibility of the model code; (3) lack of validation; and
(4) difficulty interpreting the results of technical analyses.
Despite recommendations from the US Preventive Ser-
vices Task Force intended to address these concerns,
models are still held in low regard. As part of the Stroke
PORT project, a simulation model of stroke development
and outcomes was developed. This model has since been
expanded to accommodate a variety of potential inter-
ventions and data sources and is currently designated the
Duke Stroke Policy Model (DSPM). One of the major ob-
jectives of the DSPM has been to address the above con-
cerns. Our approach has been to (1) use the best data; (2)
vigorously promote an open-code public-use application,
available on the Internet; (3) perform rigorous validation;
and (4) develop user-friendly applications based on the
validated core code, tailored to different user groups. Re-
searchers, teachers and public health professionals are
encouraged to use the DSPM for academic and other non-
commercial applications, and to engage with the develop-
ers to promote the continuing improvement of the model.
In this workshop, we will (1) lay out the set of conditions
for assessing the quality of models, (2) provide examples
from the DSPM of how these conditions may be met, and
(3) engage participants in a discussion of cases in other
clinical areas.
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OBJECTIVES: Selection bias in observational studies is
described. Instrumental variable estimation is presented
in detail as a method of identification of treatment ef-
fects. Practical issues related to the proper implementa-
tion of this technique are stressed. Propensity score meth-
ods are also discussed.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who use, evaluate, or conduct observational studies.
While estimates of treatment outcomes and costs from
randomized clinical trials are still considered the gold
standard, the use of observational data for these esti-
mates is common. Observational data are less costly to
obtain, readily available, and represent actual practice.
However, there is always a danger of selection bias when
these data are used to identify the costs or outcomes of
one particular treatment versus another. This is true even
when quality risk adjustment methods and propensity
score methods are employed. Instrumental variable esti-
mation and propensity score methods have both been
proposed to overcome the selection bias problem in ob-
servational studies. We describe selection bias and how
instrumental variables analysis and propensity score
methods overcome the problem. We then explain how
one would apply these techniques correctly to common
research problems emphasizing the importance of choos-
ing when propensity score methods are sufficient or when
instrumental variables analysis should be used.
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OBJECTIVES: To provide a detailed overview of the reg-
istry concept and implementation, emphasizing its re-
search value as well as its potential role in support of new
product development and marketing and in the develop-
ment and testing of disease management programs.
PARTICIPANTS WHO WOULD BENEFIT: Persons
who have responsibility for planning or conducting out-
comes research or disease management programs in the
pharmaceutical industry, hospitals, or managed care.
There is growing enthusiasm for the use of health-care
claims data bases representing thousands or even millions
of covered lives to assess the potential value of medical
interventions, including pharmaceuticals and disease
management programs. However, evaluations of the ef-
fectiveness and safety of such interventions conducted in
this manner may be confounded by clinical or patient dif-
ferences between treatment groups that are not captured
in readily-available databases. Patient registries designed
to meet specific research objectives can provide a more
robust source of data for outcomes research and disease
management by linking administrative data bases, medi-
cal records, patient questionnaires, death certificates, etc.
The result is comprehensive longitudinal information on
diagnosis, treatment, course of illness, outcomes, quality
of life, and costs of the diseases of interest. By seeking the
informed consent of participants the registry can also ob-
viate growing public concerns about the research use of
confidential health-care data. Workshop participants will
